3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Cyclophosphamide
7
Etoposide
5
Prednisone
4
Doxorubicin
4
Vincristine
3
romidepsin
2
pembrolizumab
2
etoposide phosphate
2
duvelisib
2
Melphalan
2
Brentuximab Vedotin
2
Azacitidine
2
10-propargyl-10-deazaaminopterin
2
tazemetostat
1
sodium-iodide symporter
1
ruxolitinib
1
prednylidene
1
glofitamab
1
fludarabine phosphate
1
fludarabine
1
deltacortene
1
cemiplimab
1
brincidofovir
1
belinostat
1
X-Rays
1
Whole-Body Irradiation
1
Valganciclovir
1
Therapeutics
1
Tacrolimus
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Immunoblastic Lymphadenopathy
×
Sunitinib
×
1 year
×
Clear all
No trials found.